Skip to main content

Table 1 Demographic and clinical characteristics of early and advanced-stages NSCLC patients in PMC cohort

From: miR-7 methylation as a biomarker to predict poor survival in early-stage non-small cell lung cancer patients

 

N = 42

Methylated

Unmethylated

p-value

PMC cohort: early-stage

Sex

 Female

6

2 (33%)

4 (67%)

1.00

 Male

36

13 (36%)

23 (64%)

Smoking status

 Current smoker

25

9 (36%)

16 (64%)

0.88

 Former smoker

13

5 (38%)

8 (62%)

 Never smoker

4

1 (25%)

3 (75%)

Tumor histologic type

 Adenocarcinoma

24

10 (42%)

14 (58%)

n.a

 Squamous

16

3 (19%)

13 (81%)

 Others

2

2 (100%)

0 (0%)

Stage

 IA

2

0 (0%)

2 (100%)

n.a

 IB

11

1 (9%)

10 (91%)

 IIA

3

0 (0%)

3 (100%)

 IIB

10

7 (70%)

3 (30%)

 IIIA

16

7 (44%)

9 (56%)

 

N = 31

Methylated

Unmethylated

p-value

PMC cohort: advanced-stage

Sex

 Female

8

6 (75%)

2 (25%)

0.67

 Male

23

17 (74%)

6 (26%)

Smoking status

 Current smoker

11

8 (73%)

3 (27%)

1.00

 Former smoker

20

15 (75%)

5 (25%)

Tumor histologic type

 Adenocarcinoma

15

12 (80%)

3 (20%)

n.a

 Squamous

14

10 (71%)

4 (29%)

 Others

2

1 (50%)

1 (50%)

Stage

 IIIB

15

11 (73%)

4 (27%)

n.a

 IIIC

2

1 (50%)

1 (50%)

 IV

14

11 (79%)

3 (21%)

RECIST

 PR

10

7 (70%)

3 (30%)

n.a

 SD

7

5 (71%)

2 (29%)

 PD

6

6 (100%)

0 (0%)

 n.a.

8

  
  1. MiR-7 methylation related to gender, smoking status, tumor histologic type, stage and RECIST. It is not possible to calculate p value because of the number of cases in each group is insufficient
  2. PR partial response, SD stable disease, PD disease progression, n.a. not available